Key terms
About GHRS
GH Research Plc operates as a holding company, which engages in the provision of biopharmaceutical products and services. It develops therapeutic products for patients of psychiatric and neurological disorders. The firm develops novel and proprietary 5-Methoxy-N and N-Dimethyltryptamine, or 5-MeO-DMT, therapies. The company was founded by Theis Terwey, Florian Schönharting, and Magnus Halle in 2018 and is headquartered in Dublin, Ireland.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest GHRS news
Mar 04
11:36am ET
Buy Rating for GH Research: Promising Clinical Trials and Strategic Intellectual Property Advances
Mar 01
6:19am ET
GH Research price target lowered to $39 from $50 at JMP Securities
Mar 01
1:36am ET
Buy Rating Justified by GH Research’s Promising Clinical Trials and Strong Financial Health
Mar 01
12:30am ET
Wall Street Analysts Are Bullish on Top Healthcare Picks
Feb 29
7:02am ET
GH Research reports FY23 EPS (68c), consensus (67c)
Jan 22
12:57pm ET
Optimistic Outlook for GH Research with Progressing Phase 2 Trials and Strong IP Portfolio Reinforcing Buy Rating
Jan 18
4:34pm ET
EPO grants GH Research patent with claims directed to 5-MeO-DMT for MDD/TRD
No recent press releases are available for GHRS
GHRS Financials
Key terms
Ad Feedback
GHRS Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
GHRS Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
